AU2005316561A1 - The uses of estrogen beta agonists to treat cognitive diseases - Google Patents

The uses of estrogen beta agonists to treat cognitive diseases Download PDF

Info

Publication number
AU2005316561A1
AU2005316561A1 AU2005316561A AU2005316561A AU2005316561A1 AU 2005316561 A1 AU2005316561 A1 AU 2005316561A1 AU 2005316561 A AU2005316561 A AU 2005316561A AU 2005316561 A AU2005316561 A AU 2005316561A AU 2005316561 A1 AU2005316561 A1 AU 2005316561A1
Authority
AU
Australia
Prior art keywords
carbon atoms
alkyl
halogen
alkenyl
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005316561A
Other languages
English (en)
Inventor
Mark Day
Heather A. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2005316561A1 publication Critical patent/AU2005316561A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2005316561A 2004-12-17 2005-12-15 The uses of estrogen beta agonists to treat cognitive diseases Abandoned AU2005316561A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17
US60/637,144 2004-12-17
PCT/US2005/045375 WO2006065968A2 (en) 2004-12-17 2005-12-15 The uses of estrogen beta agonists to treat cognitive diseases

Publications (1)

Publication Number Publication Date
AU2005316561A1 true AU2005316561A1 (en) 2006-06-22

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005316561A Abandoned AU2005316561A1 (en) 2004-12-17 2005-12-15 The uses of estrogen beta agonists to treat cognitive diseases

Country Status (20)

Country Link
US (1) US20060135574A1 (cg-RX-API-DMAC7.html)
EP (1) EP1824478A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008524236A (cg-RX-API-DMAC7.html)
KR (1) KR20070086329A (cg-RX-API-DMAC7.html)
CN (1) CN101321524A (cg-RX-API-DMAC7.html)
AR (1) AR051844A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005316561A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519111A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590258A1 (cg-RX-API-DMAC7.html)
GT (1) GT200500370A (cg-RX-API-DMAC7.html)
IL (1) IL183604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007007347A (cg-RX-API-DMAC7.html)
NI (1) NI200700152A (cg-RX-API-DMAC7.html)
NO (1) NO20072658L (cg-RX-API-DMAC7.html)
PA (1) PA8656601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20061113A1 (cg-RX-API-DMAC7.html)
RU (1) RU2007120254A (cg-RX-API-DMAC7.html)
TW (1) TW200637545A (cg-RX-API-DMAC7.html)
WO (1) WO2006065968A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705103B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
US10758496B2 (en) * 2014-09-02 2020-09-01 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2018183800A1 (en) * 2017-03-30 2018-10-04 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
TR200102992T2 (tr) * 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
JP2004515496A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
DE60116109T2 (de) * 2001-11-07 2006-09-07 Schering Ag In vitro Screening nach Liganden des Östrogenrezeptors
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
WO2004026290A1 (en) * 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
JP2008505095A (ja) * 2004-07-01 2008-02-21 ワイス エストロゲンリガンドとしての四環式化合物

Also Published As

Publication number Publication date
BRPI0519111A2 (pt) 2008-12-23
CN101321524A (zh) 2008-12-10
PA8656601A1 (es) 2006-12-07
AR051844A1 (es) 2007-02-14
WO2006065968A8 (en) 2008-09-12
IL183604A0 (en) 2007-10-31
MX2007007347A (es) 2007-07-13
RU2007120254A (ru) 2009-01-27
NO20072658L (no) 2007-09-12
WO2006065968A2 (en) 2006-06-22
PE20061113A1 (es) 2006-11-06
CA2590258A1 (en) 2006-06-22
WO2006065968A3 (en) 2008-04-10
TW200637545A (en) 2006-11-01
GT200500370A (es) 2006-07-13
NI200700152A (es) 2008-06-17
KR20070086329A (ko) 2007-08-27
JP2008524236A (ja) 2008-07-10
EP1824478A2 (en) 2007-08-29
ZA200705103B (en) 2009-11-25
US20060135574A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
CN101939017B (zh) 大麻素在与抗精神病药物组合中的用途
AU2025201645A1 (en) Methods and compositions for treating psychotic disorders
Sorbera et al. Pagoclone
CN111032089A (zh) 用于治疗应激相关障碍的组合物
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
Lladó-Pelfort et al. Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: effects of antipsychotic drugs and receptor ligands
EP2636414A1 (en) Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
WO2007124348A2 (en) Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
US20060135574A1 (en) Novel uses for estrogen beta agonists
WO2008020651A1 (fr) antagoniste de récepteur P2X4
KR20180100627A (ko) 섬망의 예방 또는 치료제
US11318122B2 (en) Pharmaceutical combination and its use for treating synucleinopathties
KR20250155546A (ko) 파킨슨병의 치료에 있어서의 메트포르민과 글리벤클라미드의 병용
JP2021505668A (ja) 併用療法(睡眠障害およびcns障害)において使用するためのnmda受容体モジュレーター(ラパスチネル)の組合せ
CN111973615A (zh) 一种治疗躁狂型精神障碍及精神分裂症的药物
BR112021012491A2 (pt) Combinações antineurodegenerativas de domperidona e uso
CA2595208A1 (en) Therapeutic agents for sensory disorders
CA2659754A1 (fr) Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
Kramar Experimental study of new 3-(2-R1-6-R2-4-oxyquinoline-3 (4H)-yl) alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound)
WO2000056292A2 (en) Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine
JP2023510173A (ja) 中枢神経系障害の処置及び防止のための化合物
Adrien et al. Neurobiology of insomnia
KR20010029658A (ko) 뇌의 아세틸콜린 방출 증강제
EA047023B1 (ru) Композиции и способы лечения расстройств, связанных со стрессом
OA21243A (en) Compounds for treatment of alzheimer's disease.

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application